Interest in this area has increased in recent reports suggesting that treatment of T2DM or obese patients with GLP-1 receptor agonists not only does not correlate with an increased incidence of PDAC484 but is also associated with a significantly decreased prevalence of pancreatic cancer compared with diabetic patients treated with insulin.485 A recent study also suggested a protective effect of GLP-1 receptor agonists486 but the possibility of adverse effects, including pancreatitis and PDAC, has been raised.487. This evidence concerns the gene GLP1R and pancreatic neoplasm.